Unlocking the Potential of SGN-CD19B: A Breakthrough in Targeting B-Cell Malignancies
In vitro studies revealed high potency against various CD19+ tumor lines, with a wide range of IC50 values. Preclinical models, including diffuse large B-cell lymphoma, Burkitt's lymphoma, and B-cell acute lymphoblastic leukemia, demonstrated significant antitumor effects at specific dosages. Notably, complete and lasting tumor regression was observed in lymphoma models at higher doses, and a substantial increase in survival was noted in a leukemia model.
Toxicology studies in monkeys indicated that SGN-CD19B is well-tolerated, with B-cell depletion observed at various doses. The depletion was reversible, with lymphoid architecture and B-cell counts returning to normal within weeks post-treatment.
The findings suggest that SGN-CD19B has potential in treating CD19+ malignancies, with plans for clinical trials to assess its efficacy in patients with relapsed or refractory non-Hodgkin lymphoma.
How to Use Synapse Database to Search and Analyze Translational Medicine Data?
The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.
Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.
By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.
Click on the image below to go directly to the Translational Medicine search interface.
